A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

This study has been terminated.
(Unable to enroll due to criteria for stable baseline pain)
Sponsor:
Collaborator:
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
OncoGenex Technologies
ClinicalTrials.gov Identifier:
NCT01083615
First received: February 26, 2010
Last updated: February 11, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)